NEW YORK (GenomeWeb News) – Illumina’s board appointed Michel Bouchard Chief Accounting Officer, effective Jan. 1. He will continue to serve as vice president of finance for the firm, as well, a title he has held since joining Illumina in 2008.
Before landing at Illumina, Bouchard held senior finance and accounting positions at Websense, and was VP Finance and Accounting from 2007 to 2008.
Sequenom has promoted several members of its management team.
William Welch is now the president and chief operating officer. He was previously senior vice president of diagnostics and has overseen the commercial operations of the MaterniT21 Plus test.
Dirk van den Boom has been appointed executive vice president of research and development and chief technology officer from his position of senior vice president of research and development, which he has held since 2010. He joined the company in 1998.
Ron Lindsay is now executive vice president of strategic planning. He was previously the executive vice president of research and development.
Pharmacogenomics company AssureRx has added four new faces to its leadership.
The company named Bryan Dechairo to be senior VP of medical affairs & strategic alliances. He formerly was head of extramural R&D at the Medco Research Institute and was neuroscience lead and director of molecular medicine at Pfizer Global R&D. He also worked in drug target discovery and diagnostic development at Roche Molecular Systems, Oxagen, and Sequana Therapeutics.
Stephen King has been appointed to be VP of marketing, where he will be responsible for overall marketing efforts and increasing awareness of the GeneSightRx product line. He previously was VP of commercial operations at Alkermes, and he worked on the launch of pharmaceutical products at SmithKline Beecham Pharmaceuticals and Wyeth.
Rao Mulpuri will take over the position of VP of lab operations, and will be responsible for multi-site commercial testing. He previously was director of scientific operations at the Catholic Health Initiatives Center for Translational Research, and he held a range of posts at Beckman Coulter Genomics, Cogenics, Clinical Data, and Paradigm Genetics.
Scott Roth will be VP of product development. He formerly was software development manager at Domin-8 Enterprise Solutions and he designed and developed software at Spotlight Solutions and at Attachmate.
Genetic Technologies has named Alison Mew to be company CEO and Ben Silluzio as a non-executive director, the company said this week.
Mew has been the company's COO for more three years, and in that position helped to establish the Australian company's US operations.
A specialist in providing investment advice, Silluzio currently is managing partner and desk head of RBS Morgans Family Office.
The Personalized Medicine Coalition this week said that Julie Goonewardene has been elected to its board of directors for a three-year term.
Goonewardene is a public member of the American Medical Association's Board of Trustees and is associate vice chancellor for innovation and entrepreneurship at the University of Kansas, as well as a professor in the KU School of Business.
Fluidigm has named Frederic Walder to serve as company COO, effective immediately, after having been company chief business officer since 2010.
From 1992 to 2010, Walder held various senior executive posts at Thermo Fisher Scientific, including spending periods as senior VP of customer excellence and division president of Thermo Electron.
Trovagene's stockholders have unanimously re-elected its board of directors to serve for another year, including Gabriele Cerrone; Gary Jacob; Thomas Adams; John Brancaccio; Antonius Schuh; and Stanley Tennant.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.